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Abstract
We reviewed articles to clarify the current evidence status for 1) types of cancer which related to benzene
exposure, and 2) certain benzene exposure level which might cause the hematopoietic cancers. Hematopoietic
function of the bone marrow is involved in the production of all blood cells types. The benzene metabolites
including benzoquinone and mucoaldehyde affect hematopoietic stem cells as well as differentiation steps of
progenitor cells for each blood cell. Hence, we concluded that benzene was associated with all lymphohematic
carcinogenesis. First, it is supported by biological plausibility. Second, it is supported by meta-analysis although sing
study did not show relationship due to lack of sample size or statistical power. More recent studies show lesser
exposed level related to risk of cancer, compare to past studies did. Actually, early studies show the risk of
malignancies in workers who exposed more than 200 ppm-years. However, only 0.5 to 1 ppm-year benzene
exposed show significant linking to risk of malignancies in recent study. As reviewed research articles, we
concluded that the relatively lower exposure level, such as 0.5–1 ppm-year, will be considering at risk of
hematopoietic cancer. However, more research needs to be done on dose-response analysis.
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Background
The International Agency for Research on Cancer
(IARC) concluded that benzene exposure has sufficient
carcinogenic evidence in both humans and animals
study in 1987 [1]. That report shows strong evidences
that benzene exposure causes acute myeloid leukemia
(AML) and acute non-lymphocytic leukemia (ANLL).
There are also positive association between benzene ex-
posure and acute/chronic lymphocytic leukemia, non-
Hodgkin lymphoma, and myeloma [2].
National Institute for Occupational Safety and Health
(NIOSH) in USA conducted cohort study of 459 ben-
zene exposure workers from 1940 through 1975 [3].
That study was undertaken using workers in Pliofilm
manufacture, and that results supported Occupational
Safety and Health Administration (OSHA) to reduce
permissible exposure limit from 10 ppm to 1 ppm [4].
Exposure standard in Korea was also established at level
of 10 ppm in 1986, but it was change to 1 ppm in 2003
to prevent leukemia patients from benzene exposure.
According to the Enforcement Decree of Industrial
Accident Compensation Insurance Acts of specific cri-
teria in 2003, “1 ppm or more benzene exposure during
10 years or more” are regarded as sufficient exposure
level to cause occupational diseases of leukemia and
multiple myeloma. Cumulative exposure exceeds
10 ppm-year is also regarded as sufficient exposure level
even though the total exposure duration is below
10 years. Furthermore, if there were no record for ben-
zene exposure in past job exposure history, the 10 years’
cumulative exposure amount is more than 1 ppm based
on current job exposure concentrations is also regarded
as a sufficient exposure level for occupational disease.
Recently, a Cohort study reported that even 1 ppm-
year or below benzene exposed workers also suffered
from leukemia [5, 6]. One ppm-year exposures are ten
times lower levels of Korea stand exposure level for
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occupational relatedness. Hence, current Korea Act of
standards for occupational diseases relatedness should
be reviewed using recent studies. We reviewed articles
to clarify the current evidence status for 1) types of can-
cer which related to benzene exposure, and 2) certain
benzene exposure level which might cause the
hematopoietic cancers.
Main text
General characteristic of benzene
Benzene is a pale yellowish liquid with molecular for-
mula C6H6, molecular weight of 78.11 and a flam-
mable substance with aromatic odor. It is almost
insoluble in water and soluble in organic solvents and
oils. Benzene reacts violently with oxidizing agent,
easy to vaporize. Benzene is absorbed into the body
through inhalation, skin exposure, and ingestion. In
animal experiments, about 50% of aspirated benzene
is absorbed into the body [7]. In the case of skin ex-
posure, the absorption rate is low because a signifi-
cant amount is vaporized before absorption, and a
high uptake rate when ingested orally. Benzene is rap-
idly metabolized mainly in the liver and becomes
water-soluble and is released into the urine within
48 h. Some of the metabolites of benzene migrate to
the bone marrow. Benzene itself appears to be non-
toxic, and the metabolites from the liver, especially
benzoquinone and mucoaldehyde, have bone marrow
toxicity [8]. These metabolites can damage DNA and
produce DNA adducts. Benzene is metabolized in dif-
ferent concentrations. At low concentrations, much of
benzene is metabolized to hydroquinone and other
toxic substances than to high concentrations.
Benzene has been used as an ingredient in inks in the
printing industry, in organic solvent solvents, as a start-
ing material and intermediate for the production of rub-
ber, lubricants, dyes, cleaners and pesticides in the
chemical and pharmaceutical industries, as an additive
to unleaded gasoline. A recent major use is the manufac-
ture of organic chemicals [2]. It is mainly used for the
production of styrene, phenol, cyclohexane, aniline, ma-
leic anhydride, alkyl benzene and chlorobenzene in
Europe and also for anthraquinone, hydroquinone, ben-
zene hexachloride, benzenesulfonic acid and drugs, dyes,
pesticides and plastics. It is also an intermediate of other
products. In Korea, it is usually used for the production
of styrene, phenol and cyclohexane. Benzene is naturally
occurring in petroleum products (crude oil, gasoline,
etc.) and is added to unleaded gasoline to increase the
octane number of unleaded gasoline and to suppress en-
gine knocking. Benzene content varies from country to
country, but about 1–2%. Petroleum benzene content
standard of Korea are currently less than 0.7% [9].
Biological mechanism of benzene on hematopoietic
cancer
Leukemia refers to the overgrowth of abnormal imma-
ture leukocytes caused by cancer derived from blood it-
self or bone marrow cell. Word Health Organization
classified leukemia according to precursor cells of
lymphocytic and myeloid [10]. Both precursor cells of
lymphocyte and myeloid cells are derived from same
hematopoietic stem cells by the cell differentiation
process [11]. There are also scientific reports that certain
cells have both characteristics of lymphoid and myeloid
cell even after differentiation process [12]. Hence, we
used the word of “hematopoietic cancer” for all types of
blood cell malignancies.
Hematopoietic function of the bone marrow is in-
volved in the production of all blood cells types, and
hematopoietic stem cells are differentiated into the an-
cestral cells of each blood cell type. Thereafter, various
blood cells are produced by self-renewal and differenti-
ation of each ancestral cells. The benzene metabolites
including benzoquinone and mucoaldehyde affect
hematopoietic stem cells as well as differentiation steps
of progenitor cells for each blood cell. Consequently,
benzene metabolites may affect all leukemic stem cells
of all blood cell type in every step [13, 14]. Thus, there
are biological plausibility the benzene exposure and its
metabolites can cause all types of hematopoietic tumors
derived from hematopoietic stem cell [15].
Despite the biological causality that benzene can cause
all hematopoietic cancer, IARC has reported that other
blood cancers have limited relevance to benzene, except
in the case of ANLL, AML [2]. The reason for this can
be explained by the low incidence of diseases except
ANLL.
In adults, the incidences of other malignant
hematopoietic diseases except AML are too low to eluci-
date association from epidemiological studies. From
2006 to 2010, the incidence of AML increased rapidly
after age 40, which is much higher than that of the inci-
dence of acute lymphoblastic leukemia (ALL) [16]. Simi-
larly, Korean’s data show high incident rate of AML
compare to that of ALL [17]. Those low incidence level
of ALL may explain current status of lack of epidemio-
logical evidence between benzene exposure and ALL in-
cidence. If the relatively low incidence is cause of lack of
evidence, the large prospective cohort study will give
more realistic scientific evidence. Alternatively, meta-
analysis of gathering multiple studies can solve the such
low incidence related problem. Hence, we estimate
Meta-Standardized mortality ratio (SMR) using by stud-
ies which published IARC reports [2].
We conducted a meta-analysis of five cohort studies in
which ALL was found in more than 5 cases of exposure
among 10 cohort studies in which IARC report [2].
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Finally, 5 studies were selected: Yin et all 1996, Saint et
all 1996, Rushton et all 1993, Divin et all 1999. Among 5
studies, only one study of Saint et all show statistical sig-
nificant evidence between benzene exposure and ALL
(relative risk (RR) =2.59, 95% confidence interval (CI) =
1.12 to 5.11). In contrary to Saint’s study, others did not
show statistical significance. However, the pooling of
those RR got statistical significance in Meta-analysis.
The Meta-SMR is 1.96 and it’s 95% CI is 1.25 to 2.95
(Fig. 1). Current result of meta-analysis suggest that rela-
tively large cohort or relatively high incidence disease
can get statistical significant even those relationships did
not statistical significant when using relatively small
sample size or low incidence diseases.
In the same contexts, incidence of multiple myeloma
is lower than that of ALL. Infante et all undertook meta-
analysis using seven studies [18]. The incidences of indi-
vidual studies due to benzene exposure were very low
and there was no statistically significant result except for
one study. However, meta-analysis showed a statistically
significant and positive correlation between benzene ex-
posure and multiple myeloma [18]. The SMR (95% CI)
of each studies are 4.35 (0.1–24.2), 4.09 (1.1–10.5), 3.57
(0.4–12.9), 2.88 (0.6–8.4), 0.40 (0.1–10.7), 1.90 (0.8–3.8),
0.72 (0.2–2.1). However, the pooled estimation show sig-
nificant relationship between multiple myeloma and
benzene exposure (RR = 2.13, 95% CI = 1.31–3.46) [18].
In summary, the metabolism of benzene influences the
whole process of hematopoietic differentiation that starts
from hematopoietic stem cells. Hence, benzene exposure
can cause all type of hematopoietic malignancies. Large-
scale studies are required to obtain sufficient numbers of
cases for other types of hematopoietic cancer, except for
AML, in which epidemiological evidence is not yet suffi-
cient. Alternatively, the results of meta-analysis result
supported that biological plausibility by epidemiological
concepts.
Benzene exposure level and risk of hematopoietic
malignancies
The analysis of cumulative benzene exposure and
hematopoietic cancer development is as follows.
(1) Research by Wong et al. [19]
Wong et al. quantified the exposure and calculated the
standardized mortality ratio (SMR) from the cohort data
of workers in the factory in the US using Pliofilm (a
transparent sheet made from hydrochloric rubber). Risk
of AML did not be increased in 200 ppm-year exposure
group, but SMRs (95% CI) for AML were sharply in-
creased in 200 ppm-year exposure or more group. The
SMRs (95% CI) for AML were 27.2 (3.3–98.0) and 98.3
(20.3–287.6) in 200–400 ppm-year and more than
400 ppm-year exposed group, respectively.
(2) Research by Hayes et al. [20]
Hayes et al. found a relative risk (RR) according to
the exposure level of Acute non-lymphocytic leukemia
(ANLL) in follow-up data of benzene exposed / unex-
posed workers at 672 plants in 12 Chinese cities. RR
(95% CI) of ANLL was 1.9 (95% CI: 0.5–7.0) in less
than 20 ppm-year exposed group. However, RRs (95%
CI) of ANLL were 4.3 (1.1–16.0) and 3.6 (1.1–11.6)
in 40–99 ppm-years and 100 ppm-year or more ex-
posed group, respectively. The risk of ANLL was also
estimated according to average level of benzene ex-
posure. The RRs (95% CI) of ANLL were 2.0 (0.6–7.
0), 5.8 (1.8–18.9) and 2.6 (0.7–9.9) in exposed group
of less than 10 ppm, 10–24 ppm and more than
24 ppm, respectively. In summary, significant incre-
ment of risk for ANLL was observed in 40 ppm-year
of cumulative exposure and 10 ppm of average expos-
ure group.
(3) Study of Schnatter et al. [21]
Schnatter et al. reported a significant increase in
the incidence of myelodysplastic syndrome (MDS) at
low concentrations of benzene exposure after updat-
ing the cohort of Australian, Canadian, and British
oil workers. The cumulative exposures of 2.93 ppm-
years group show high risk of MDS compare to less
than 0.35 ppm-year exposed group. The RR (95% CI)
of MDS was 4.33 (1.31–14.3) in 2.93 ppm-years or
more exposed group. The RR (95% CI) of MDS was
6.32 (1.32–30.2) when highest exposure level
exceeded over 3 ppm.
(3) Research by Glass et al. [22, 23]
In the “Health Watch” study of Glass et al., which
followed up 16,000 Australian workers from 1980 to
1998, 79 hematologic malignancies cases occurred
(Glass et al., 2001). In a nested case-control study
using 395 control groups, the cumulative exposure
was calculated as ppm-year and divided into 5 levels
to identify the risk of malignancies. The concentra-
tions of the lowest exposed group were 0.005 ppm-
year to 0.33 ppm-year, followed exposed group was
1.42 ppm-year, 3.53 ppm-year, and 7.82 ppm-year. 18
cases of malignancies were observed in the third
level cumulative exposure group, and RR (95% CI) of
hematologic malignancies was 2.54 (1.05–6.18). In
Fig. 1 Meta-Analysis for ALL SMR using 5 studies of IARC report (ALL:
acute lymphoblastic leukemia, SMR: Standardized mortality ratio)
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the fourth exposed group, the RR (95% CI) did not show
significant relationship, 2.20 (0.89–5.43). In contrary to
that, 22 cases were observed in the fifth exposed group
and RR (95% CI) was 3.32 (1.40–7.91). Glass et al. did not
undertook the trend analysis. We undertook Cochran-
Armitage Trend Test using reported number of cases and
controls in published article of Glass et al. The p value of
trend analysis was 0.011 (below 0.05). Hence, we con-
cluded that cumulative exposure of 1.46 ppm-year or
more significantly related to risk of hematopoietic
malignancy.
Glass et al. (2005) reanalyzed this cohort and found
that OR (95% CI) of workers with cumulative expo-
sures in excess of 8 ppm-year benzene exposure was
7.2 (1.3–40.4) compare to worker who exposed less
than 4 ppm-year [23]. For all types of leukemia, the
risk was significantly increased in more than 2 ppm
– years exposed group. In the group exposed to less
than 10 years, benzene exposed group was divided by
cut level of 0.5 ppm-year, 1 ppm-year, 2 ppm-year,
4 ppm-year and 8 ppm-year or more. The RR (95%
CI) was 2.27 (1.14–4.54) in 0.5-1 ppm-year exposed
group when comparing the risk in less than 0.
5 ppm-year exposed group. Thus, workers who ex-
posed benzene only 0.5 ppm-year or more during
10 years are at risk of ANLL. In other words, ex-
posed to 0.05 ppm for 10 years or more can be con-
sidered to be associated with a higher risk of
hematopoietic cancers in that study.
In summary, more recent studies show lesser ex-
posed level related to risk of cancer, compare to
past studies did. Actually, early studies show the
risk of malignancies in workers who exposed more
than 200 ppm-years. However, only 0.5 to 1 ppm-
year benzene exposed show significant linking to
risk of malignancies in recent study. This
phenomenon may be observed in other occupational
diseases such as heavy metal induced diseases. In
the high exposure period, it is not easy to find non-
exposure group. Hence, the non-healthy reference
group might be control group in relatively high ex-
posed period or society. Non-healthy reference or
exposed reference group may make underestimate of
risk. Hence, the cut level of statistical significant
easy upward in that period. In the contrary to that,
the lower exposed period can find heathy reference
and non-exposed reference in same factory or same
research design. It supported by research of Glass
et al. Hence, the recently result that 0.5–1 ppm-year
benzene exposure significantly related to
hematopoietic cancer can give us important mes-
sage. Hence, recent studies suggest that 0.5 to
1 ppm-year benzene exposure significantly related to
risk of lymphohematic malignancies.
Conclusions
Finally, it was concluded that benzene was associated
with all lymphohematic carcinogenesis. First, it is sup-
ported by biological plausibility. Second, it is supported
by meta-analysis although sing study did not show rela-
tionship due to lack of sample size or power. In relation
between the cumulative exposure of benzene and
hematopoietic cancer, the relatively lower exposure level,
such as 0.5–1 ppm-year, will be considering at risk level.
However, more research needs to be done on dose-
response analysis.
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